Companies › RDC Clinical
10 active drug programs in 47 registered trials: 17 Phase 2, 14 Phase 4, 13 Phase 3, 3 Phase 1; Other, Neurology, Psychiatry, Immunology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| life's Omega 1035DS Microalgal-derived omega-3 (EPA/DHA) formulation | – | Phase 4 | Optimal Absorption of Omega-3 | Apr 2027 |
| life's Omega O3020DS Microalgal-derived omega-3 (EPA/DHA) formulation | – | Phase 4 | Optimal Absorption of Omega-3 | Apr 2027 |
| Aquacelle® Omega 3 Omega-3 fatty acid supplement (EPA and DHA) | – | Phase 4 | Healthy Volunteer | Sep 2027 |
| Cholecalciferol Vitamin D receptor agonist | VDR | Phase 4 | Healthy Volunteer; COVID-19; Bronchiectasis; Osteoarthritis … | Sep 2027 |
| Caffeine Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 4 | Exercise; Migraine; Healthy; Vibration Therapy … | – |
| Testofen 300mg Fenugreek seed extract (traditional herbal testosterone support) | – | Phase 3 | Erectile Dysfunction | – |
| Lavender Oil (CPO Lavender oil) Herbal supplement; mechanism in sleep/stress not fully established | – | Phase 2 | Sleep Disorder (Disorder) | Feb 2027 |
| Oleoylethanolamide (Trpti) Endocannabinoid-like compound; TRPV1 and PPAR-alpha agonist with appetite regulation and s | TRPV1, PPARA | Phase 2 | Sleep Disorder (Disorder); Healthy Volunteers | Feb 2027 |
| Palmitoylethanolamide (PEA) Endocannabinoid-like lipid signaling molecule; acts as agonist at TRPV1 and PPARα receptor | TRPV1, PPARA | Phase 2 | Sleep Disorder (Disorder); Healthy; Persistent Postural Perceptual Dizziness | Feb 2027 |
| Levagen+ (palmitoylethanolamide, PEA) Lipid signaling molecule; TRPV1 antagonist and PPARδ agonist with anti-inflammatory and ne | TRPV1, PPARD | Phase 2 | Diabetic Peripheral Neuropathy | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04482673 | Cholecalciferol | Phase 4 | COVID-19 | Infectious disease | Dec 2022 |
| NCT04482673 | Cholecalciferol | Phase 4 | COVID-19 | Infectious disease | Dec 2022 |
| NCT07022496 | Caffeine | Phase 4 | Migraine | Neurology | Jul 2025 |
| NCT04775381 | Cholecalciferol | Phase 3 | Hypocalcemia | Metabolic and endocrine | Dec 2025 |
| NCT07469852 | Caffeine | Phase 1 | Caffeine | Other | Mar 2026 |
| NCT07028528 | Levagen+ (palmitoylethanolamide, PEA) | Phase 2 | Diabetic Peripheral Neuropathy | Neurology | May 2026 |
| NCT05232279 | Testofen 300mg | Phase 3 | Erectile Dysfunction | Genitourinary | Jul 2026 |
| NCT05232279 | Testofen 300mg | Phase 3 | Erectile Dysfunction | Genitourinary | Jul 2026 |
| NCT02178410 | Cholecalciferol | Phase 3 | Cardiovascular Disease | Cardiovascular | Oct 2026 |
| NCT07434752 | Caffeine | Phase 4 | Exercise | Other | Oct 2026 |
| NCT04677816 | Cholecalciferol | Phase 2 | Triple Negative Breast Cancer | Oncology | Dec 2026 |
| NCT06327152 | Caffeine | Phase 2 | Apnea of Prematurity | Other | Dec 2026 |
| NCT01419730 | Cholecalciferol | Phase 2 | Bone Metabolism Biomarkers | Other | Dec 2026 |
| NCT06551337 | Cholecalciferol | Phase 4 | Bronchiectasis | Respiratory | Dec 2026 |
| NCT03613116 | Cholecalciferol | Phase 2 | Vitamin D Deficiency | Metabolic and endocrine | Dec 2026 |
| NCT06763172 | Caffeine | Phase 4 | Healthy | Other | Dec 2026 |
| NCT07315516 | Palmitoylethanolamide (PEA) | Phase 2 | Sleep Disorder (Disorder) | Psychiatry | Feb 2027 |
| NCT07315516 | Lavender Oil (CPO Lavender oil) | Phase 2 | Sleep Disorder (Disorder) | Psychiatry | Feb 2027 |
| NCT07315516 | Oleoylethanolamide (Trpti) | Phase 2 | Sleep Disorder (Disorder) | Psychiatry | Feb 2027 |
| NCT07921810 | Caffeine | Phase 4 | Vibration Therapy | Other | Mar 2027 |
| NCT03516968 | Cholecalciferol | Phase 3 | Obesity, Childhood | Metabolic and endocrine | Mar 2027 |
| NCT03516968 | Cholecalciferol | Phase 3 | Obesity, Childhood | Metabolic and endocrine | Mar 2027 |
| NCT07457723 | Oleoylethanolamide (Trpti) | Phase 2 | Healthy Volunteers | Other | Mar 2027 |
| NCT06629103 | life's Omega 1035DS | Phase 4 | Optimal Absorption of Omega-3 | Other | Apr 2027 |
| NCT06629103 | life's Omega O3020DS | Phase 4 | Optimal Absorption of Omega-3 | Other | Apr 2027 |
| NCT06741358 | Palmitoylethanolamide (PEA) | Phase 4 | Persistent Postural Perceptual Dizziness | Immunology | May 2027 |
| NCT06508099 | Cholecalciferol | Phase 2 | Acute Lymphoblastic Leukemia | Oncology | May 2027 |
| NCT07006714 | Cholecalciferol | Phase 4 | Osteoarthritis | Immunology | Jul 2027 |
| NCT03188796 | Cholecalciferol | Phase 3 | Critical Illness | Infectious disease | Jul 2027 |
| NCT00856947 | Cholecalciferol | Phase 1 | Asthma | Respiratory | Jul 2027 |
| NCT07177157 | Cholecalciferol | Phase 1 | Ulcerative Colitis (UC) | Immunology | Jul 2027 |
| NCT06717867 | Palmitoylethanolamide (PEA) | Phase 2 | Healthy | Other | Aug 2027 |
| NCT07791797 | Aquacelle® Omega 3 | Phase 4 | Healthy Volunteer | Other | Sep 2027 |
| NCT07791797 | Cholecalciferol | Phase 4 | Healthy Volunteer | Other | Sep 2027 |
| NCT04094688 | Cholecalciferol | Phase 3 | Colorectal Adenocarcinoma | Oncology | Dec 2027 |
| NCT04570085 | Caffeine | Phase 3 | Alzheimer Disease | Neurology | Dec 2027 |
| NCT03768492 | Caffeine | Phase 2 | Carcinoma Breast | Oncology | Dec 2027 |
| NCT06757244 | Cholecalciferol | Phase 2 | Pancreas Neoplasms | Oncology | Feb 2028 |
| NCT05174611 | Cholecalciferol | Phase 2 | Anterior Cruciate Ligament Injuries | Other | Mar 2028 |
| NCT02112734 | Cholecalciferol | Phase 4 | Food Allergy | Immunology | Apr 2028 |
| NCT05043116 | Cholecalciferol | Phase 2 | Asthma in Children | Respiratory | Oct 2028 |
| NCT07269457 | Cholecalciferol | Phase 2 | Traumatic Brain Injury (TBI) Patients | Neurology | Dec 2028 |
| NCT07647198 | Cholecalciferol | Phase 2 | Uterine Fibroids (Leiomyoma) | Oncology | Aug 2029 |
| NCT07448974 | Cholecalciferol | Phase 3 | Prediabetes | Metabolic and endocrine | Mar 2030 |
| NCT04442412 | Cholecalciferol | Phase 3 | Diffuse Large B-Cell Lymphoma | Oncology | Sep 2030 |
| NCT01169259 | Cholecalciferol | Phase 3 | Cancer | Oncology | Mar 2031 |
| NCT06570889 | Cholecalciferol | Phase 3 | Asthma | Respiratory | Mar 2033 |
Valenta Pharm JSC Heron Therapeutics Ipsen Kowa Company Zydus Therapeutics Inventiva Pharma OPKO Health Gilead Sciences Can-Fite BioPharma
Mylan Pharmaceuticals Mesoblast ROKIT Healthcare MaaT Pharma Photozig
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.